Compare GOVX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOVX | MBOT |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 126.3M |
| IPO Year | N/A | N/A |
| Metric | GOVX | MBOT |
|---|---|---|
| Price | $0.18 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 3.7M | 2.0M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,353,560.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,119.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $0.12 | $1.08 |
| 52 Week High | $2.75 | $4.67 |
| Indicator | GOVX | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 25.64 | 38.43 |
| Support Level | $0.16 | $2.06 |
| Resistance Level | $0.22 | $2.14 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 20.64 | 5.83 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.